Details for Patent: 9,139,536
Which drugs does patent 9,139,536 protect, and when does it expire?
Patent 9,139,536 protects VIEKIRA XR and VIEKIRA PAK (COPACKAGED) and is included in two NDAs.
This patent has forty-six patent family members in twenty-one countries.
Summary for Patent: 9,139,536
| Title: | Anti-infective agents and uses thereof |
| Abstract: | This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. |
| Inventor(s): | Charles A. Flentge, Douglas K. Hutchinson, David A. Betebenner, David A. Degoey, Pamela L. Donner, Warren M. Kati, Allan C. Krueger, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, Christopher E. Motter, John K. Pratt, John T. Randolph, Todd W. Rockway, Kent D. Stewart, Rolf Wagner, Shuang Chen, Yi Gao, Xiaochun Lou, Geoff G. Z. Zhang |
| Assignee: | AbbVie Inc |
| Application Number: | US13/838,223 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,139,536
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | 9,139,536 | ⤷ Start Trial | TREATMENT OF HCV INFECTION USING DASABUVIR | ⤷ Start Trial | ||||
| Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | DISCN | Yes | No | 9,139,536 | ⤷ Start Trial | TREATMENT OF HCV INFECTION USING DASABUVIR | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,139,536
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2203431 | ⤷ Start Trial | 15C0013 | France | ⤷ Start Trial |
| European Patent Office | 2203431 | ⤷ Start Trial | CA 2015 00014 | Denmark | ⤷ Start Trial |
| European Patent Office | 2203431 | ⤷ Start Trial | C20150015 00143 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
